Scleroderma Diagnostics and Therapeutics Market (Drug Class - Corticosteroids, Immunosuppressive Agents, Endothelin Receptor Agonists, Calcium Channel Blockers, PDE-5 Inhibitors, Chelating Agents, Prostacyclin Analogues, H2 Blockers, Proton Pump Inhibitors, and ACE Inhibitors; Indication - Localized and Systemic; Diagnostic Test Type - Skin Biopsy, Imaging Techniques, Blood Test, Electrocardiogram and Echocardiogram, and Pulmonary Function Tests) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017 - 2030

Description

Global Scleroderma Diagnostics and Therapeutics Market: Snapshot

The scleroderma therapeutics and diagnostics market exhibits high potential due to untapped needs and is set to grow rapidly in the near future due to the increasing focus globally on treatment of orphan diseases. The lack of approved drugs in the market makes it a highly opportune condition for players to convert their innovative drug ideas into successful treatment methods for this rare chronic inflammatory disease.

The global scleroderma diagnostics and therapeutics market was valued at US$1,689.7 mn in 2017 and is projected to expand at a CAGR of 10.3% from 2017 to 2024 to reach US$3,663.8 mn by 2024.

Physician and Patient Preference to make Immunosuppressive Agents Leading Drug Category

Presently, there is no approved drug for treatment of this orphan disease. Although drugs to manage symptomatic relief are available in the scleroderma therapeutics market, the treatment of scleroderma is challenging for a physician, since no two patients are alike in the progress of their disease. Thus, a host of different drugs are prescribed to every patient, depending on the extent, severity and nature of their symptoms.

It has been observed that patient consumption patterns in the global scleroderma diagnostics and therapeutics market are inclined towards immunosuppressive agents, which have shown to provide relief against several symptoms in both systemic and localized scleroderma cases. Moreover, of the very few treatments identified to efficaciously modify the course of scleroderma, physicians often recommend immunosuppressive agents to manage the most common symptoms of the disease. The segment, as a result, accounts for the dominant share in the global market.

Prostacyclin analogues have been found to have a potent effect in treating systemic scleroderma patients who suffer from pulmonary arterial hypertension. However, these drugs are expensive and thus, even though a smaller sub-set of patients is administered with these agents, their market value is high. This segment grabbed a significant share of the global scleroderma therapeutics market in the recent past; however, the share of this segment is anticipated to slightly decline by 2024 owing to availability of cheaper alternatives within this segment.

Developed Regions to Continue to Command Dominance

Owing to better diagnostic and treatment rates, in part due to proactive awareness-raising initiatives by various foundations, have aided North America and Europe gain the predominant share in the global scleroderma diagnostics and therapeutics market. North America and Europe held significant share of the global scleroderma therapeutics market in the recent past. This is attributed to presence of renowned pharmaceutical companies, research organizations, and institutes in the regions, which are focused on finding a standard treatment for the condition.

The North America and Europe markets for scleroderma diagnostics and therapeutics are expected to retain their dominance in the global scleroderma diagnostics and therapeutics market throughout the forecast period, exhibiting significant CAGR over the period between 2017 and 2024. The ongoing cutting-edge research pertaining to scleroderma will aid the growth of a niche scleroderma diagnostics and therapeutics market in these regions.

Asia Pacific represents some of the world’s key emerging economies, which have the potential to adopt quickly to new therapies, provided they are available at reasonable costs. Due to the price-sensitive nature of the market, as well as availability of cheaper generics and reasonable clinical diagnostic rates compared to North America and Europe, the market for Asia Pacific gained the third position in terms of market share in 2015. The Asia Pacific market will also retain its position in the global market over the forecast period, with factors such as large population and high unmet needs working in favor of market expansion in the region.

Actelion Pharmaceuticals, Inc., Boehringer Ingelheim, Bayer AG, Cytori Therapeutics, Inc., Corbus Pharmaceutical Holdings Inc, Cumberland Pharmaceuticals, Inc., Gilead Sciences, Inc., Pfizer, Inc., and Sanofi are some of the key players operating in the global scleroderma diagnostics and therapeutics market.

Global Scleroderma Diagnostics and Therapeutics Market: Research Methodology

The report has been prepared after an elaborate primary and secondary research phase. Thus, the analysis of the scleroderma diagnostics and therapeutics market presented in reliable to a high degree. The primary research phase involved carrying out telephonic as well face-to-face interviews with industry experts along with e-mail interactions. Primary research represent major part of research efforts along with a secondary research phase. Industry stakeholders who participated in the primary research phase include CEOs, VPs, market intelligence managers, marketing/product managers, and national sales managers. Purchasing managers, technical experts, suppliers and traders were some other stakeholders who were reached out in the primary research phase. Rheumatologists, dermatologists, and physicians treating scleroderma patients were also reached out in the primary research phase of the making of the report.

Secondary research phase involved reaching out to industry-centric databases for data collection followed by data scrutiny. Secondary sources reached out include key players’ product literature, annual reports, relevant business documents, and trade journals. Some other secondary sources reached out include trade journals, technical writings, government websites, trade associations, Internet sources, and online paid databases.

Secondary research sources reached out for the study include stock analyst websites, company website sources, governmental organizations and public portals, Orange Book – FDA, U.S. Centers for Disease Control and Prevention, European Centre for Disease Prevention and Control, Clinicaltrials.gov, Clinicaltrialsregister.eu, journals and other publications.

TABLE OF CONTENT

Chapter 1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights

Chapter 2. Assumptions and Research Methodology

Chapter 3. Executive Summary: Global Scleroderma Diagnostics and Therapeutics Market

Chapter 4. Market Overview
4.1. Introduction
        4.1.1. Drug Class Definition
        4.1.2. Industry Developments
4.2. Market Dynamics
        4.2.1. Drivers
        4.2.2. Restraints
        4.2.3. Opportunity
4.3. Porters Five Forces Analysis
4.4. Global Scleroderma Diagnostics and Therapeutics Market Analysis and Forecasts, 2014–2024
4.5. Scleroderma Diagnostics and Therapeutics Market Outlook
4.6. Scleroderma : Overview of Clinical Trials

Chapter 5. Global Scleroderma Therapeutics Market Analysis and Forecasts, By Indication 
5.1. Key Findings
5.2. Introduction
5.3. Market Size (US$ Mn) Forecast, by Indication
        5.3.1. Localized
        5.3.2. Systemic
5.4. Market Attractiveness Analysis, by Indication, 2015
5.5. Key Trends and Developments

Chapter 6. Global Scleroderma Therapeutics Market Analysis and Forecasts, By Drug Class
6.1. Key Findings
6.2. Introduction
6.3. Market Size (US$ Mn) Forecast, by Drug Class
        6.3.1. Corticosteroids
        6.3.2. Immunosuppressive Agents
        6.3.3. Endothelin receptor antagonists 
        6.3.4. Calcium Channel Blockers
        6.3.5. PDE-5 Inhibitors
        6.3.6. Chelating Agents
        6.3.7. Prostacyclin analogues
        6.3.8. Others 
6.4. Market Attractiveness Analysis, by Drug Class, 2015
6.5. Key Trends and Developments

Chapter 7. Global Scleroderma Therapeutics Market Analysis and Forecasts, By Region
7.1. Key Findings
7.2. Introduction
7.3. Market Size (US$ Mn) Forecast, by Region
        7.3.1. North America
        7.3.2. Europe
        7.3.3. Asia Pacific
        7.3.4. Latin America
        7.3.5. Middle East & Africa
7.4. Market Attractiveness Analysis, by Region, 2015
7.5. Key Trends

Chapter 8. North America Scleroderma Therapeutics Market Analysis and Forecast
8.1. Key Findings
8.2. Introduction
8.3. Market Size (US$ Mn) Forecast, by Indication 
        8.3.1. Localized
        8.3.2. Systemic
8.4. Market Size (US$ Mn) Forecast, by Drug Class
        8.4.1. Corticosteroids
        8.4.2. Immunosuppressive Agents
        8.4.3. Endothelin receptor antagonists 
        8.4.4. Calcium Channel Blockers
        8.4.5. PDE-5 Inhibitors
        8.4.6. Chelating Agents
        8.4.7. Prostacyclin analogues
        8.4.8. Others 
8.5. Market Size (US$ Mn) Forecast, by Country
        8.5.1. U.S.
        8.5.2. Canada
8.6. Market Attractiveness Analysis, by Indication, 2015
8.7. Market Attractiveness Analysis, by Drug Class, 2015
8.8. Key Trends

Chapter 9. Europe Scleroderma Therapeutics Market Analysis and Forecast
9.1. Key Findings
9.2. Introduction
9.3. Market Size (US$ Mn) Forecast, by Indication
        9.3.1. Localized
        9.3.2. Systemic
9.4. Market Size (US$ Mn) Forecast, by Drug Class
        9.4.1. Corticosteroids
        9.4.2. Immunosuppressive Agents
        9.4.3. Endothelin receptor antagonists 
        9.4.4. Calcium Channel Blockers
        9.4.5. PDE-5 Inhibitors
        9.4.6. Chelating Agents
        9.4.7. Prostacyclin analogues
        9.4.8. Others 
9.5. Market Size (US$ Mn) Forecast, by Country
        9.5.1. U.K.
        9.5.2. Germany
        9.5.3. France
        9.5.4. Rest of Europe
9.6. Market Attractiveness Analysis, by Indication 2015 
9.7. Market Attractiveness Analysis, by Drug Class, 2015
9.8. Key Trends

Chapter 10. Asia Pacific Scleroderma Therapeutics Market Analysis and Forecast
10.1. Key Findings
10.2. Introduction
10.3. Market Size (US$ Mn) Forecast, by Indication
        10.3.1. Localized
        10.3.2. Systemic
10.4. Market Size (US$ Mn) Forecast, by Drug Class
        10.4.1. Corticosteroids
        10.4.2. Immunosuppressive Agents
        10.4.3. Endothelin receptor antagonists 
        10.4.4. Calcium Channel Blockers
        10.4.5. PDE-5 Inhibitors
        10.4.6. Chelating Agents
        10.4.7. Prostacyclin analogues
        10.4.8. Others 
10.5. Market Size (US$ Mn) Forecast, by Country
        10.5.1. China
        10.5.2. India
        10.5.3. Japan
        10.5.4. Rest of Asia Pacific
10.6. Market Attractiveness Analysis, by Indication, 2015 
10.7. Market Attractiveness Analysis, by Drug Class, 2015
10.8. Key Trends

Chapter 11. Latin America Scleroderma Therapeutics Market Analysis and Forecast
11.1. Key Findings
11.2. Introduction
11.3. Market Size (US$ Mn) Forecast, by Product 
        11.3.1. Localized
        11.3.2. Systemic
11.4. Market Size (US$ Mn) Forecast, by Distribution Channel
        11.4.1. Corticosteroids
        11.4.2. Immunosuppressive Agents
        11.4.3. Endothelin receptor antagonists 
        11.4.4. Calcium Channel Blockers
        11.4.5. PDE-5 Inhibitors
        11.4.6. Chelating Agents
        11.4.7. Prostacyclin analogues
        11.4.8. Others 
11.5. Market Size (US$ Mn) Forecast, by Country
        11.5.1. Brazil
        11.5.2. Mexico
        11.5.3. Rest of Latin America
11.6. Market Attractiveness Analysis, by Indication, 2015 
11.7. Market Attractiveness Analysis, by Drug Class, 2015
11.8. Key Trends

Chapter 12. Middle East & Africa Radiodermatitis Market Analysis and Forecast
12.1. Key Findings
12.2. Introduction
12.3. Market Size (US$ Mn) Forecast, by Indication 
        12.3.1. Localized
        12.3.2. Systemic
12.4. Market Size (US$ Mn) Forecast, by Drug Class
                12.4.1. Corticosteroids
        2.4.2. Immunosuppressive Agents
        12.4.3. Endothelin receptor antagonists 
        12.4.4. Calcium Channel Blockers
        12.4.5. PDE-5 Inhibitors
        12.4.6. Chelating Agents
        12.4.7. Prostacyclin analogues
        12.4.8. Others 
12.5. Market Size (US$ Mn) Forecast, by Country
        12.5.1. UAE
        12.5.2. South Africa
        12.5.3. Rest of Middle East & Africa
12.6. Market Attractiveness Analysis, by Indication, 2015 
12.7. Market Attractiveness Analysis, by Drug Class, 2015
12.8. Key Trends

Chapter 13. Competition Landscape
13.1. Competition Matrix
13.2. Company Profiles
        13.2.1. Actelion Pharmaceuticals, Inc. 
                  13.2.1.1. Company Overview (HQ, Business Segments, Employee Strength)
                  13.2.1.2. Financial Overview
                  13.2.1.3. Product Portfolio
                  13.2.1.4. SWOT Analysis
                  13.2.1.5. Strategic Overview
        13.2.2. Bayer AG
                  13.2.2.1. Company Overview (HQ, Business Segments, Employee Strength)
                  13.2.2.2. Financial Overview
                  13.2.2.3. Product Portfolio
                  13.2.2.4. SWOT Analysis
                  13.2.2.5. Strategic Overview
        13.2.3. Boehringer Ingelheim
                  13.2.3.1. Company Overview (HQ, business segments, employee strength)
                  13.2.3.2. Product Portfolio
                  13.2.3.3. SWOT Analysis
                  13.2.3.4. Financial Overview
                  13.2.3.5. Strategic Overview
        13.2.4. Corbus Pharmaceutical Holdings, Inc. 
                  13.2.4.1. Company Overview (HQ, business segments, employee strength)
                  13.2.4.2. Product Portfolio
                  13.2.4.3. SWOT Analysis
                  13.2.4.4. Strategic Overview
                  13.2.4.5. Key Developments
        13.2.5. Cumberland Pharmaceuticals Inc.
                  13.2.5.1. Company Overview (HQ, business segments, employee strength)
                  13.2.5.2. Financial Overview
                  13.2.5.3. Product Portfolio
                  13.2.5.4. SWOT Analysis
                  13.2.5.5. Strategic Overview
        13.2.6. Cytori Therapeutics, Inc.
                  13.2.6.1. Company Overview (HQ, business segments, employee strength)
                  13.2.6.2. Product Portfolio
                  13.2.6.3. SWOT Analysis
                  13.2.6.4. Financial Overview
                  13.2.6.5. Strategic Overview
        13.2.7. F. Hoffmann La Roche Ltd. 
                  13.2.7.1. Company Overview (HQ, business segments, employee strength)
                  13.2.7.2. Financial Overview
                  13.2.7.3. Product Portfolio
                  13.2.7.4. SWOT Analysis
                  13.2.7.5. Strategic Overview
        13.2.8. Gilead Sciences, Inc. 
                  13.2.8.1. Company Overview (HQ, business segments, employee strength)
                  13.2.8.2. Financial Overview
                  13.2.8.3. Product Portfolio
                  13.2.8.4. SWOT Analysis
                  13.2.8.5. Strategic Overview
        13.2.9. Merck KGaA
                  13.2.9.1. Company Overview (HQ, business segments, employee strength)
                  13.2.9.2. Product Portfolio
                  13.2.9.3. Financial Overview
                  13.2.9.4.  SWOT Analysis
                  13.2.9.5. Strategic Overview
        13.2.10. Pfizer, Inc.
                  13.2.10.1. Company Overview (HQ, business segments, employee strength)
                  13.2.10.2. Product Portfolio
                  13.2.10.3. Financial Overview
                  13.2.10.4. SWOT Analysis
                  13.2.10.5. Strategic Overview
        13.2.11. Sanofi
                  13.2.11.1. Company Overview (HQ, business segments, employee strength)
                  13.2.11.2. Product Portfolio
                  13.2.11.3. Financial Overview
                  13.2.11.4. SWOT Analysis
                  13.2.11.5. Strategic Overview

Choose License Type

Checkout Inquiry Sample